Latest News
Beyond the Benchmark: A Four-Layer Framework for Evaluating Healthcare AI
Healthcare AI is often evaluated where it is easiest to measure: on a dataset. Accuracy, sensitivity, specificity, calibration, retrieval quality, hallucination rates and task-completion scores all matter. But they answer only the first question: can the model perform...
Latest News
The Next Era of Cardiorenal Care Is Precision Fluid Management
Medicine has become increasingly specialized over the past several decades, driving tremendous advances in our ability to diagnose and treat complex diseases. Specialists now possess deeper expertise than ever before, allowing clinicians to deliver highly targeted...
Clinical Trials Roundup | 21 Aug 2026
Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
The Ketogenic Diet: Why Long-Term Safety Deserves Greater Scrutiny
The ketogenic diet has transitioned from a highly specialized therapeutic intervention to a widely promoted dietary strategy for weight loss, metabolic health, inflammation, and, in some circles, cancer prevention or treatment. Its popularity has outpaced the strength...
Human-in-the-Loop or Human-on-the-Loop? Pharma’s AI Authority Test
“But what can this AI model actually do?” It’s a common question being asked across the life sciences industry. Can it classify a symptom, summarize a trial record, predict a molecule’s behavior, or monitor a manufacturing process? Those capabilities matter, but they...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Physical Activity and Dementia: The Evidence Base Is Uneven
The link between physical activity and dementia depends on where that activity happens, according to a meta analysis of 74 studies covering more than four million adults. Leisure time exercise was associated with a lower risk of dementia, while activity undertaken at...
The Next Recruitment Challenge Isn’t Awareness, It’s Qualification
For years, the clinical research industry has focused heavily on one question: How do we reach more patients? Digital advertising, social media campaigns, patient advocacy partnerships, and online recruitment platforms have dramatically expanded researchers' ability...
From Digital Transformation to Operational Intelligence in Healthcare
Healthcare has never really had a technology problem. The greater challenge has been turning technology into better ways of working. Over the past decade, healthcare organizations have invested heavily in electronic health records, digital services, automation,...
Fatty Pancreas Disorder and the New Era of Integrated Obesity Management
Obesity is increasingly recognized as a chronic systemic disease characterized not only by excess adiposity but also by progressive dysfunction of multiple organs. Recent advances have shifted attention from body weight alone toward ectopic fat deposition as a major...
Rethinking Biomedical Research in the Age of AI
The paradox of modern biomedical research Biomedical research has never generated so much knowledge, and researchers have never struggled so much to keep pace with it. PubMed now indexes more than 40 million references drawn from roughly 26,000 journals[1]....
Australia Marks 40 years of Daffodil Day on Thursday 20 August
Cancer Council calls on Australians to help fund the next 40 years of breakthroughs One of Australia's most iconic and enduring fundraising campaigns, Daffodil Day, will return on Thursday 20 August 2026, marking 40 years of Australians coming together to support...
Retatrutide Black Market: Lilly Sues Six US Sellers
Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...
Modeling T Cell Dysfunction: New Frontiers in Immunometabolism
While cancer immunotherapies—particularly immune checkpoint blockades (ICBs)—have transformed clinical oncology, primary and acquired resistance remain major hurdles in solid tumors. Mounting evidence reveals that this non-responsiveness is deeply tied to the...
Beyond Tolvaptan: The Next Generation of ADPKD Therapies
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...
What Trauma Taught Me That Medical School Never Did
Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...
CAR-T Therapy Explained: A Plain-English Guide
CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...
Beyond Detection: What Our Microplastics Study Means for Clinical Practice
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
Physical Activity and Dementia: The Evidence Base Is Uneven
The link between physical activity and dementia depends on where that activity happens, according to a meta analysis of 74 studies covering more than four million adults. Leisure time exercise was associated with a lower risk of dementia, while activity undertaken at...
The Next Recruitment Challenge Isn’t Awareness, It’s Qualification
For years, the clinical research industry has focused heavily on one question: How do we reach more patients? Digital advertising, social media campaigns, patient advocacy partnerships, and online recruitment platforms have dramatically expanded researchers' ability...
From Digital Transformation to Operational Intelligence in Healthcare
Healthcare has never really had a technology problem. The greater challenge has been turning technology into better ways of working. Over the past decade, healthcare organizations have invested heavily in electronic health records, digital services, automation,...
Fatty Pancreas Disorder and the New Era of Integrated Obesity Management
Obesity is increasingly recognized as a chronic systemic disease characterized not only by excess adiposity but also by progressive dysfunction of multiple organs. Recent advances have shifted attention from body weight alone toward ectopic fat deposition as a major...
Rethinking Biomedical Research in the Age of AI
The paradox of modern biomedical research Biomedical research has never generated so much knowledge, and researchers have never struggled so much to keep pace with it. PubMed now indexes more than 40 million references drawn from roughly 26,000 journals[1]....
Australia Marks 40 years of Daffodil Day on Thursday 20 August
Cancer Council calls on Australians to help fund the next 40 years of breakthroughs One of Australia's most iconic and enduring fundraising campaigns, Daffodil Day, will return on Thursday 20 August 2026, marking 40 years of Australians coming together to support...
Retatrutide Black Market: Lilly Sues Six US Sellers
Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...
Modeling T Cell Dysfunction: New Frontiers in Immunometabolism
While cancer immunotherapies—particularly immune checkpoint blockades (ICBs)—have transformed clinical oncology, primary and acquired resistance remain major hurdles in solid tumors. Mounting evidence reveals that this non-responsiveness is deeply tied to the...
Beyond Tolvaptan: The Next Generation of ADPKD Therapies
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...
What Trauma Taught Me That Medical School Never Did
Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...
CAR-T Therapy Explained: A Plain-English Guide
CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...
Beyond Detection: What Our Microplastics Study Means for Clinical Practice
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
Featured Articles
Further News
Weekly News Roundup | 17 August 2026
Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...
Crohn’s, Colitis and Conception: Building a Family with IBD
When treating individuals with inflammatory bowel disease (IBD), either Crohn's disease or ulcerative colitis, I’m often asked: "Will this stop me having children?". Given that IBD affects around 180,000 Australians and is typically first diagnosed between the ages of...
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints
Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...
Panthera Opens New Clinical Research Clinic at Keele University
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...
Clinical Trials Roundup | 14 Aug 2026
Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...
From Laboratory to Market: Risk Planning for Life Science Companies
The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...
Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze
Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...
Organ Digital Twins: Inside Imperial College London’s Research
Organ digital twins have moved from mathematical curiosity to funded national priority. Imperial College London now sits close to the centre of that shift. Researchers there have built more than 3,800 anatomically accurate virtual hearts. They have also begun an NHS...
Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS
Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...
Kidney Care’s $2.5 Billion Timing Problem
Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...
Blood Supplies Set For Vital Boost as Donation Rules Are Updated
Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...
In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained
In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.